Aurisco Expands Oligonucleotide Capacity and Launches New Website
SETÚBAL, Portugal, April 20, 2023 /PRNewswire/ -- On its 25th anniversary, Aurisco Pharmaceutical, an innovative pharmaceutical CRDMO (contract research, development and manufacturing organization) announced the expansion of its oligonucleotide manufacturing capacity and a new edition of its corporate website – www.aurisco.com.
- The New State-of-Art OligoPilot 2000™ solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
- SETÚBAL, Portugal, April 20, 2023 /PRNewswire/ -- On its 25th anniversary, Aurisco Pharmaceutical, an innovative pharmaceutical CRDMO (contract research, development and manufacturing organization) announced the expansion of its oligonucleotide manufacturing capacity and a new edition of its corporate website – www.aurisco.com .
- The new OligoPilot 2000™ solid-phase synthesizer, from Cytiva, completes Aurisco Biotech's pilot scale cGMP plant and provides immediate capacity availability to accelerate customer's clinical programs as well as Aurisco's generic oligonucleotide pipeline.
- The new website has been designed to offer a more user-friendly experience with more information, improved navigation and new communication functionalities.